FDA criticised for rejecting over the counter emergency contraceptionBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7527.1223-a (Published 24 November 2005) Cite this as: BMJ 2005;331:1223
- Janice Hopkins Tanne
- New York
The US Food and Drug Administration's decision to refuse to approve over the counter status for the emergency contraceptive Plan B (levonorgestrel) was flawed, unusual, and not standard FDA procedure. This is finding of a report by the Government Accountability Office, an independent investigative agency of the US Congress.
Two FDA officials resigned in protest over the denial (BMJ 2005;331: 532, 861).
Forty eight senators and representatives …